Robotic secondary cytoreductive surgery is becoming a pivotal tool in the treatment of recurrent ovarian cancer. Clinicians recognize that achieving complete gross resection significantly improves patient survival. While many surgeons previously preferred open laparotomy, robotic-assisted techniques now offer a reliable minimally invasive alternative. This approach is particularly effective for oligometastatic cases where precision is paramount.

Implementing Robotic Secondary Cytoreductive Surgery

A recent case highlights the success of this method in a woman in her 40s with platinum-sensitive recurrence. Surgeons identified three distinct metastatic sites including the cardiophrenic lymph nodes and the hepatic hilum. Additionally, they found interaortocaval lymphadenopathy below the renal vein. By utilizing the robotic platform, the surgical team accessed these complex anatomical regions with high precision. Consequently, they achieved complete cytoreduction without any intraoperative complications.

Furthermore, the procedure demonstrated excellent efficiency and safety metrics. The total operation time lasted 200 minutes, and the patient lost only 100 mL of blood. This outcome is impressive considering the extensive adhesiolysis required from previous surgeries. Notably, preoperative 3D reconstruction served as a critical guide for the surgical planning phase. Therefore, the integration of advanced imaging and robotic technology facilitates superior clinical results.

Multidisciplinary Success in Complex Oncology

Expert surgeons must work within a multidisciplinary team to ensure the best outcomes for patients. Specifically, patient selection remains the most important factor when deciding on a robotic approach. However, the ability to treat extrapelvic recurrence across multiple sites marks a significant milestone in gynecologic oncology. Ultimately, robotic-assisted surgery offers a personalized and effective pathway for managing recurrent ovarian cancer.

Frequently Asked Questions

Is robotic secondary cytoreductive surgery effective for multi-site recurrence?

Yes, clinical data show that robotic platforms allow for successful resection in multiple anatomical regions for selected patients. However, success depends heavily on surgical expertise and the specific volume of the disease.

Why is 3D reconstruction important for this surgery?

3D reconstruction creates a spatial map of tumors relative to vital organs and blood vessels. This mapping helps surgeons navigate safely during the robotic procedure and ensures they remove all visible cancerous tissue.

How does the recovery compare to open surgery?

In addition to reduced blood loss, robotic surgery typically leads to shorter hospital stays and faster recovery times. This allows patients to potentially resume subsequent treatments, such as chemotherapy, much sooner.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Certelli C et al. Robotic Secondary Cytoreductive Surgery: A Personalized Surgical Approach For a Triple-Site Ovarian Cancer Recurrence. Ann Surg Oncol. 2026 Feb 10. doi: 10.1245/s10434-026-19120-3. PMID: 41665786.

Galli V et al. Analysis of secondary cytoreduction for recurrent ovarian cancer by robotics, laparoscopy and laparotomy. NIH PubMed. https://pubmed.ncbi.nlm.nih.gov/22607738/

Li M et al. Perioperative and Survival Outcomes of Robotic-Assisted Surgery, Comparison with Laparoscopy and Laparotomy, for Ovarian Cancer: A Network Meta-Analysis. PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063259/